Vox Sanguinis最新文献

{"title":"Short-term temperature excursion does not affect plasma and cryoprecipitate quality.","authors":"Kelly M Winter, Rachel G Webb, Eugenia Mazur, Peta M Dennington, Denese C Marks","doi":"10.1111/vox.70302","DOIUrl":"10.1111/vox.70302","url":null,"abstract":"<p><strong>Background and objectives: </strong>Plasma and cryoprecipitate are stored below -25°C for optimal preservation of component quality. However, there may be situations in which components are exposed to higher temperatures and therefore discarded. This study aimed to determine the quality of plasma and cryoprecipitate following a short-term temperature excursion to inform a possible shelf life.</p><p><strong>Materials and methods: </strong>Apheresis and whole blood (WB)-derived fresh frozen plasma (FFP; n = 68 and n = 37, respectively) and cryoprecipitate components (apheresis n = 78 and WB n = 80) that incurred a temperature excursion up to -11°C were returned to -25°C. Coagulation factors were measured at 1 month (baseline), 3 months and 6 months post excursion.</p><p><strong>Results: </strong>There were no significant differences in factor VIII (FVIII) concentrations in apheresis- and WB-derived plasma and apheresis-derived cryoprecipitate between 1 month, 3 months and 6 months (p = 0.236, p = 0.249 and p = 0.815, respectively). Activated partial thromboplastin time and prothrombin time increased slightly in plasma over storage but were not significantly different from baseline. Fibrinogen, von Willebrand Factor (VWF), protein C and immunoglobulin G were stable in plasma and cryoprecipitate.</p><p><strong>Conclusion: </strong>The data demonstrate that plasma and cryoprecipitate that incurred a temperature excursion can meet quality control specifications when stored for 6 months post temperature excursion.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1420-1424"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of nucleic acid testing for transfusion safety in a country without deferral of men who have sex with men: Epidemiology of HIV among Polish blood donors and residual transfusion-transmission risk, 2005-2023.","authors":"Ewa Sulkowska, Ewa Noceń, Izabela Gordziejewska, Anna Chrzanowska, Dorota Kubicka-Russel, Aneta Kopacz, Aleksandra Kalińska, Marion Vermeulen, Piotr Grabarczyk","doi":"10.1111/vox.70306","DOIUrl":"10.1111/vox.70306","url":null,"abstract":"<p><strong>Background and objectives: </strong>In Poland, human immunodeficiency virus (HIV) prevalence in the general population is lower than in other developed countries, and men who have sex with men (MSM) are not deferred from donating blood. The aim of the study was to analyse the epidemiology of HIV in Polish blood donors after the introduction of mandatory HIV RNA screening (for the period 2005-2023).</p><p><strong>Materials and methods: </strong>HIV test results using anti-HIV (third- or fourth-generation tests) and HIV RNA using transcription-mediated amplification or PCR methods (individual donations [IDT]-minipool [MP] 24) were analysed in 23,215,295 donations from 11,179,429 donors.</p><p><strong>Results: </strong>The mean infection rate per 100,000 donors was 6.48 for all and 6.22 and 0.26 for seropositive and seronegative infections, respectively. Seronegative infections occurred 5.8 (1.4-25)-fold more often in repeat donors than in first-time donors. Almost 25% of HIV-infected donors donated blood within 100 days since HIV acquisition (analysis of Fiebig scale). In four donors, discordant results were identified, indicating elite controller infection, antiretroviral treatment (ART) or HIV prophylaxis and vaccination. No HIV transmission by transfusion was recorded in look-back, and the residual risk for red blood cells (RBCs) (Weusten model) dropped from 0.129 for MP24 at the beginning to 0.019 for MP6 and 0.0051 per million units for - Individual donation-nuclec acid testing, recently.</p><p><strong>Conclusion: </strong>The HIV incidence in blood donors in Poland, compared to other developed countries, was high, despite the low rates reported by epidemiological surveillance. NAT is an effective addition to serological screening in reducing residual risk of HIV transmission by possible test-seeking blood donors in Poland.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1356-1365"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma donation rates and infection risk: A multicentre observational study in Denmark.","authors":"Kathrine Agergård Kaspersen, István Barkos, Lotte Hindhede, Susan Mikkelsen, Khoa Manh Dinh, Nanna Brøns, Jacob Træholt, Christina Mikkelsen, Jakob Thaning Bay, Ole Birger Vesterager Pedersen, Sisse Rye Ostrowski, Erik Sørensen, Bitten Aagaard, Mie Topholm Bruun, Henrik Hjalgrim, Klaus Rostgaard, Henrik Ullum, Erzsébet Horváth-Puhó, Christian Erikstrup","doi":"10.1111/vox.70300","DOIUrl":"10.1111/vox.70300","url":null,"abstract":"<p><strong>Background and objectives: </strong>The demand for plasma-derived medicinal products underscores the need to assess health effects of plasma donation. This study examines the association between plasma donation rates and infection risk in a country with voluntary, non-remunerated donation.</p><p><strong>Materials and methods: </strong>From 2016 to 2024, 45,615 first-time plasma donors were enrolled in a cohort study with time-varying exposure. Follow-up began 90 days after the first plasma donation, with donation rates recalculated every 90 days. Donation rates were categorized as 0, 1 (reference), 2-3, 4-5 or 6-8 donations. Infection was defined using Danish health registers. Survival models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>The median plasma donation rate was 2 (Q1, 1; Q3, 4). During follow-up, 15,498 donors experienced an infection. A trend of decreasing HRs for infection was observed with higher donation rates compared with a single donation (0 donations: HR: 0.89, 95% CI: 0.86-0.93; 2-3 donations: HR: 0.85, 95% CI: 0.81-0.89; 4-5 donations: HR: 0.65, 95% CI: 0.59-0.72; and 6-8 donations: HR: 0.48, 95% CI: 0.36-0.62). Findings were consistent across multiple regression models.</p><p><strong>Conclusion: </strong>In this study, higher plasma donation rates were associated with lower infection risk. Importantly, this inverse association is likely due to bias inherent to observational designs, particularly the internal healthy donor effect, which limits interpretation. Thus, no causal relationship between plasma donation rates and infection risk can be inferred. This underscores the challenges of assessing plasma donation safety using non-randomized data.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1312-1321"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.","authors":"Susanne Marschner, Caroline R Alquist, Bethany Brown, Joseph D Rice, Christina Gloor, Jeremiah Gorman, Rebecca L Sedjo, Emily Mason, Jack P Rhodes, Phillip López, Neeta Rugg, Richard Cook, Samantha E Mack","doi":"10.1111/vox.70318","DOIUrl":"10.1111/vox.70318","url":null,"abstract":"<p><strong>Background and objectives: </strong>Di(2-ethylhexyl) phthalate (DEHP) has been classified as a reproductive toxicant and endocrine disruptor and will be banned in the European Union (EU) in blood bags starting in July 2030. Alternative plasticizers are being developed, and this study is the first to report on platelets and plasma collected using investigational non-DEHP apheresis sets.</p><p><strong>Materials and methods: </strong>Randomized, crossover collections of platelet and plasma products from identical participants in DEHP and non-DEHP sets were performed. Plasma was studied as fresh frozen plasma (FFP) and stored in non-DEHP bags. Additional plasma-only collections evaluated plasma frozen within 24 h after phlebotomy and held at room temperature for up to 24 h (PF24RT24). Platelet and plasma quality parameters were evaluated against the US Food and Drug Administration (FDA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) criteria.</p><p><strong>Results: </strong>Platelet products (n = 33 pairs) met all FDA/EDQM standards, and in vitro parameters were within the predetermined 20% equivalency margin. FFP products (n = 33 pairs) met the EDQM criteria. Factor VIII retention after ≥30 days of frozen storage was on average 88.4%. All parameters for PF24RT24 products (n = 31 pairs) met the 20% equivalency margin after >31 days of frozen storage. No serious adverse events in study participants were reported.</p><p><strong>Conclusion: </strong>Non-DEHP apheresis disposable sets collect transfusion-quality platelet and plasma components, supporting the phasing out of DEHP and reducing exposure to this plasticizer, without compromising participant safety and quality of the collected products.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1338-1346"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148309641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chagas disease in Canadian blood donors: 15 years of selective testing.","authors":"Sheila F O'Brien, Mindy Goldman, Antoine Lewin, Samra Uzicanin, Wenli Fan, Steven J Drews","doi":"10.1111/vox.70299","DOIUrl":"10.1111/vox.70299","url":null,"abstract":"<p><strong>Background and objectives: </strong>Chagas disease (Trypanosoma cruzi), prevalent in Mexico, Central and South America, can be transfusion-transmitted. Selective serological testing of blood donors was implemented over 15 years ago. We describe the trends in infections and characteristics of donors selected for testing.</p><p><strong>Materials and methods: </strong>Donor selection for testing was based on birth in Latin America and/or mother/grandmother born in Latin America and/or travel to Latin America (30 days duration at Héma-Québec [HQ], 6 months at Canadian Blood Services [CBS]). All first-time donors (2010-2024) were analysed. Frequencies were compiled by gender, age group, region and residential material deprivation and ethnocultural composition indices. Multiple logistic regression compared donors with risk factors (tested) versus those without risk factors (not tested).</p><p><strong>Results: </strong>Of the 67,490 tested donors, most were born in Mexico, Central or South America (71% at CBS). Of the 27 donors positive for T. cruzi antibodies, more were from Ontario, materially deprived and ethnocultural concentrated neighbourhoods. One had mother/grandmother birth, but none had travel as the sole risk factor. Tested donors were similar to non-tested donors except more likely to be aged 30-49 (odds ratio [OR] 1.4, 1.37-1.44 CBS, 1.57, 1.51-1.63 HQ) and live in more ethnoculturally concentrated neighbourhoods (OR 2.09, 2.01-2.18 CBS, 3.46, 3.29-3.64 HQ).</p><p><strong>Conclusion: </strong>Birth in Latin America captures most T. cruzi antibody positive donations. Mother/grandmother risk occasionally yields a positive donation, but travel history does not. Infections in donors are rare, but selective testing interdicts a small risk of T. cruzi positive blood products being released into inventory.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1347-1355"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a national donor vigilance system: An example of improved donor health by reduction of delayed bleedings after donor plasmapheresis.","authors":"Pia Braagaard Hartfelt, Christina Mikkelsen, Bitten Aagaard, Rune Larsen, Sys Hasslund, Louise Ørnskov Drechsler, Mark H Yazer, Mie Topholm Bruun","doi":"10.1111/vox.70307","DOIUrl":"10.1111/vox.70307","url":null,"abstract":"<p><strong>Background and objectives: </strong>In Denmark, all blood banks use the same standardized donor vigilance system, enabling comparisons of adverse reactions across the country's five regions. At several collection sites, a compression bandage is applied over the venipuncture site after donation. In this study, we investigate whether using a compression bandage is more effective than using a non-compression bandage in preventing delayed bleeding.</p><p><strong>Materials and methods: </strong>Data were collected from four of the Danish regions (data from the fifth region were incomplete) between 2021 and 2024 using the Danish donor vigilance system. In one region, compression bandage has been used consistently since 2021, whereas three other regions transitioned from non-compression bandages to compression bandages at different times during the study period.</p><p><strong>Results: </strong>Data from 426,250 donor plasmaphereses were analysed; 160,547 (37.7%) were collected without the compression bandage and 265,703 (62.3%) were collected with the bandage. A significantly lower number of delayed bleeding events occurred when the bandage was applied post-donation (0.3% vs. 0.04%, respectively, p < 0.001).</p><p><strong>Conclusion: </strong>The implementation of the compression bandage resulted in a significant decrease in delayed bleeding in Danish plasma donors. Using a compression bandage may be an easy and cost-efficient way to improve donation safety.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1425-1429"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red cell alloantibodies in 71,525 Malaysian blood donations: Predominance of anti-Mia reflects GP.Mur-associated antigenic diversity.","authors":"Christina Lai Ling Lee, Muhammad Amir Rasyid Ahmad Makmom, Jun Fai Yap, Zhuo Lin Chong, Norliza Mustafa, Shi Ya Chang, Mohammad Izzad Bin Ishak","doi":"10.1111/vox.70320","DOIUrl":"10.1111/vox.70320","url":null,"abstract":"<p><strong>Background and objectives: </strong>Red cell alloantibody prevalence in blood donors is generally low, but antibody profiles vary according to population antigenic distribution. Data from Southeast Asia remain limited, particularly for antibodies associated with the glycophorin (GP).Mur phenotype.</p><p><strong>Materials and methods: </strong>This retrospective cross-sectional study analysed 71,525 voluntary whole blood donations at a tertiary hospital in Malaysia between 2019 and 2024. Donor demographic and laboratory data were retrieved from the laboratory information system. Antibody screening was performed using the indirect antiglobulin test with in-house pooled screening cells incorporating Mi(a+). Positive samples underwent antibody identification using commercial panels. Univariable logistic regression was used to assess demographic determinants.</p><p><strong>Results: </strong>Overall alloantibody prevalence was 0.4%. The most frequent specificities were anti-Mia (19.1%) and anti-M (17.5%). Among clinically significant antibodies, anti-Mia accounted for 72.1% (49/68), followed by anti-E, anti-c, anti-S and anti-Diᵃ. Increasing age was associated with higher odds of alloantibody positivity. Discordant antibody profiles were observed in repeat donors, consistent with antibody evanescence.</p><p><strong>Conclusion: </strong>Donor alloantibody epidemiology in Malaysia is characterized by a distinct spectrum dominated by anti-Mia, reflecting GP.Mur-associated antigenic diversity. Standard screening panels lacking Mi(a+)-expressing cells may under-detect clinically significant antibodies. Region-specific screening strategies and strengthened haemovigilance systems are required to optimize transfusion safety in Southeast Asia.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1410-1419"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel reagent for the screening of Immunoglobulin A-deficient blood donors.","authors":"Naoko Watanabe-Okochi, Ayaka Sato, Akira Okuyama, Go Tomiyoshi, Yumi Suzuki, Yukiko Watanabe, Masako Anazawa, Takashige Shimoyamada, Daisuke Takahashi, Takayuki Onodera, Makoto Uchikawa, Shigeki Miyata","doi":"10.1111/vox.70305","DOIUrl":"10.1111/vox.70305","url":null,"abstract":"<p><strong>Background and objectives: </strong>Immunoglobulin A (IgA) deficiency occurs in approximately 1 in 14,000 individuals in Japan. Approximately 32% harbour anti-IgA, most of which are naturally occurring and rarely cause anaphylaxis, although high-titre anti-IgA from alloimmunization can cause severe reactions. A stable supply of IgA-deficient plasma is essential for minimizing this risk. We therefore developed a novel reagent for large-scale identification of IgA-deficient donors.</p><p><strong>Materials and methods: </strong>Four mouse monoclonal anti-IgA-producing cell lines were established using the hybridoma method after immunizing mice with IgA protein. Purified antibodies were conjugated to carboxylate-modified polystyrene latex beads for IgA measurement using the latex agglutination method on an automated analyser. Samples with low IgA concentrations were re-tested by enzyme-linked immunosorbent assay (ELISA) for confirmation.</p><p><strong>Results: </strong>Adoption of a dual antibody assay design achieved a detection limit of 0.4 mg/dL, suitable for high-throughput screening. Screening of 24,977 randomly selected donor samples between February 2022 and April 2023 yielded 4 low IgA cases. IgA deficiency was verified by supplemental ELISA, which was required solely for these four samples. Three of four had IgA levels <0.05 mg/dL, which is the most common threshold for identifying IgA-deficient donors.</p><p><strong>Conclusion: </strong>We have developed a new reagent for detecting IgA deficiency. The assay is automatable and appears useful for large-scale screening of blood donors.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1322-1329"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and improvement of Chinese Haemovigilance Network from 2018 to 2023.","authors":"Ling Li, Bo Pan, Bangqiang Zhu, Hui Huang, Xiaoyu Guan, Yaling Zhou, Liu He, Jue Wang, Zhong Liu","doi":"10.1111/vox.70303","DOIUrl":"10.1111/vox.70303","url":null,"abstract":"<p><strong>Background and objectives: </strong>This study aimed to investigate the evolving data trends of the Chinese Haemovigilance Network (CHN) and provide insights into its future development.</p><p><strong>Materials and methods: </strong>Data were collected from the CHN covering the period of 2018-2023. The data were subdivided into three phases and analysed from several aspects. We also compared the percentage distribution of adverse transfusion reactions (ATRs) between the CHN and other national haemovigilance reports.</p><p><strong>Results: </strong>Overall, the number of hospitals participating in reporting ATRs has increased, from a total of 188 in 2018-2019 to 206 in 2020-2021 and 222 in 2022-2023. The CHN received 6410 ATRs cases: 1915 in 2018-2019, 2265 in 2020-2021 and 2230 in 2022-2023. The reports for all three phases covered 11 types of ATRs that involved transfusion of nine blood components. The highest percentage of ATRs was caused by apheresis platelets (591/1915 in 2018-2019, 756/2265 in 2020-2021 and 760/2230 in 2022-2023). In terms of ATR severity, no severity was overwhelming (91.70% in 2018-2019, 95.74% in 2020-2021 and 93.34% in 2022-2023). The CHN report showed a higher proportion of allergic reactions compared to serious hazards of transfusion. Similarly, differences in the distribution of ATRs were also observed between the CHN system and both the Australian and transfusion and transplantation reactions in patients haemovigilance systems.</p><p><strong>Conclusion: </strong>Over the past 6 years, the CHN has established a relatively advanced haemovigilance system. Comparison of the CHN and other national haemovigilance reports revealed differences in the classification and percentage distribution of ATRs, underscoring the need for standardized reporting to enhance global transfusion safety.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1376-1384"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of additive solutions on haematocrit measurement and red blood cell integrity: A comparative study of SAGM and PAGGSM.","authors":"Anaïs Lagrange, Nadine Marpaux, Pascal Amireault, Michael Dussiot, Quentin Brebant","doi":"10.1111/vox.70358","DOIUrl":"https://doi.org/10.1111/vox.70358","url":null,"abstract":"<p><strong>Background and objectives: </strong>Accurate haematocrit (Ht) measurement of red cell concentrates (RCCs) is critical because it is used to calculate the level of haemolysis, a key RCC quality control parameter. The hypothesis was that Ht depends on both the measurement method (microcapillary vs. haematology analysers) and the additive solution (hypertonic saline-adenine-glucose-mannitol [SAGM] vs. isotonic phosphate-adenine-glucose-guanosine-saline-mannitol [PAGGSM]). We quantified method- and solution-related effects on Ht measurement and assessed the downstream consequences for haemolysis. Storage-induced micro-erythrocytes (SMEs) were evaluated as a secondary marker of morphological preservation.</p><p><strong>Materials and methods: </strong>RCCs were produced from whole blood (N = 16). Using a pool-and-split design, eight paired RCCs were assigned to SAGM or PAGGSM and stored for 21 days. Ht was measured by HT200 microcapillary and haematology analysers. Red blood cell (RBC) morphology and SMEs were assessed by imaging flow cytometry.</p><p><strong>Results: </strong>At Day 1, microcapillary Ht in PAGGSM exceeded analyser-derived Ht by 3.6%-10%, whereas SAGM Ht was more consistent. Using different Ht sources materially altered haemolysis estimates. Over storage, PAGGSM showed a decline in Ht (65.3%-62.6%) accompanied by reduced RBC projected surface area (73.9-71.01 μm²). SAGM showed stable Ht but reduced RBC projected surface area (72.6-69.1 μm²). SME accumulation was lower in PAGGSM at Day 21 (13.6%) than in SAGM (18.8%).</p><p><strong>Conclusion: </strong>Ht measurement method materially impacts haemolysis, underscoring the need to standardize Ht assessment and to prefer microcapillary Ht when calculating haemolysis. Additive solution also influences storage quality: PAGGSM better preserved RBC morphology and reduced SMEs relative to SAGM up to Day 21.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148832647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}